Drug Trial Radar · NCT07023614
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
165
Planned (sponsor's estimate)
Start
Oct 6, 2025
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Imbria Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxstat compared to placebo on top of Standard of Care in patients with symptomatic nHCM
Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
Interventions
Ninerafaxstat 200mg MRDrug
Ninerafaxstat 200mg Modified Release tablet administered BID
PlaceboDrug
Matching placebo tablet administered BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)Time frame: Baseline to Week 12
Locations
76 sites in 11 countries. Site status is shown where the registry gives one.
Imbria Investigational Site
La Jolla, California · Recruiting
Imbria Investigational Site
Los Angeles, California · Recruiting
Imbria Investigational Site
San Francisco, California · Recruiting
Imbria Investigational Site
Washington D.C., District of Columbia · Recruiting
Imbria Investigational Site
Miami, Florida · Recruiting
Imbria Investigational Site
Atlanta, Georgia · Not yet recruiting
Imbria Investigational Site
Chicago, Illinois · Recruiting
Imbria Investigational Site
Oak Lawn, Illinois · Not yet recruiting
Imbria Investigational Site
Baltimore, Maryland · Recruiting
Imbria Investigational Site
Boston, Massachusetts · Recruiting
Imbria Investigational Site
Burlington, Massachusetts · Recruiting
Imbria Investigational Site
Grand Rapids, Michigan · Recruiting
Imbria Investigational Site
Rochester, Minnesota · Recruiting
Imbria Investigational Site
St Louis, Missouri · Recruiting
Imbria Investigational Site
New York, New York · Recruiting
Imbria Investigational Site
New York, New York · Not yet recruiting
Imbria Investigational Site
Charlotte, North Carolina · Recruiting
Imbria Investigational Site
Portland, Oregon · Recruiting
Imbria Investigational Site
Philadelphia, Pennsylvania · Recruiting
Imbria Investigational Site
Philadelphia, Pennsylvania · Recruiting
Imbria Investigational Site
Houston, Texas · Recruiting
Imbria Investigational Site
Houston, Texas · Not yet recruiting
Imbria Investigational Site
Plano, Texas · Recruiting
Imbria Investigational Site
Salt Lake City, Utah · Not yet recruiting
Imbria Investigational Site
Charlottesville, Virginia · Recruiting
Imbria Investigational Site
Richmond, Virginia · Recruiting
Imbria Investigational Site
Milwaukee, Wisconsin · Not yet recruiting
Imbria Investigational Site
Graz, Austria · Recruiting
Imbria Investigational Site
Edegem, Belgium · Recruiting
Imbria Investigational Site
Montpellier, France · Recruiting
Imbria Investigational Site
Paris, France · Recruiting
Imbria Investigational Site
Saint-Herblain, France · Recruiting
Imbria Investigational Site
Bad Oeynhausen, Germany · Recruiting
Imbria Investigational Site
Göttingen, Germany · Recruiting
Imbria Investigational Site
Heidelberg, Germany · Recruiting
Imbria Investigational Site
Jena, Germany · Not yet recruiting
Imbria Investigational Site
Bologna, Italy · Not yet recruiting
Imbria Investigational Site
Florence, Italy · Recruiting
Imbria Investigational Site
Massa, Italy · Recruiting
Imbria Investigational Site
Milan, Italy · Recruiting
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.